Nature Communications (Jan 2024)

Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex

  • Fabian Giehler,
  • Michael S. Ostertag,
  • Thomas Sommermann,
  • Daniel Weidl,
  • Kai R. Sterz,
  • Helmut Kutz,
  • Andreas Moosmann,
  • Stephan M. Feller,
  • Arie Geerlof,
  • Brigitte Biesinger,
  • Grzegorz M. Popowicz,
  • Johannes Kirchmair,
  • Arnd Kieser

DOI
https://doi.org/10.1038/s41467-023-44455-w
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) drives viral B cell transformation and oncogenesis. LMP1’s transforming activity depends on its C-terminal activation region 2 (CTAR2), which induces NF-κB and JNK by engaging TNF receptor-associated factor 6 (TRAF6). The mechanism of TRAF6 recruitment to LMP1 and its role in LMP1 signalling remains elusive. Here we demonstrate that TRAF6 interacts directly with a viral TRAF6 binding motif within CTAR2. Functional and NMR studies supported by molecular modeling provide insight into the architecture of the LMP1-TRAF6 complex, which differs from that of CD40-TRAF6. The direct recruitment of TRAF6 to LMP1 is essential for NF-κB activation by CTAR2 and the survival of LMP1-driven lymphoma. Disruption of the LMP1-TRAF6 complex by inhibitory peptides interferes with the survival of EBV-transformed B cells. In this work, we identify LMP1-TRAF6 as a critical virus-host interface and validate this interaction as a potential therapeutic target in EBV-associated cancer.